• Friedrich-Bergius-Ring 15
  • 97076 Würzburg
  • Germany
  • Phone: +49-(0)-931-250-99-712
  • moc.xruc-t@ofni
Dr. Ulf Grawunder, CEO T-CURX GmbH

Dr. Ulf Grawunder, CEO

About T-CURX

T-CURX GmbH is a private German early-stage biopharmaceutical company focused on identifying, developing and commercializing next generation CAR-T cell therapies in cancer indications of high medical need. The company´s proprietary CAR-T technologies were developed in the labs of co-founder Prof. Michael Hudecek at Universitätsklinikum Würzburg and are centered around a novel Sleeping Beauty (SB) Transposon gene transfer technology, which is exclusively licensed to T-CURX. T-CURX has a development pipeline of 4 CAR-T programs, the first product is in clinical development (Ph I), the 2nd CAR-T program (novel target) is ready for clinical trial application. Additional proprietary technologies that will be leveraged in T-CURX’ developing CAR-T cell product pipeline include, the proprietary Matchmaker technology for optimized potency and efficacy of T-CURX’ CAR-T cell products as well as a proprietary safety-switch that allows to control the function of CAR-T cells after infusion into patients to improve patient safety.

What is your motivation?

CAR-T cells represent the most effective therapy for blood cancer patients with remarkable rates of complete remission, even in patients who otherwise only had months to live. However, current CAR-T products are manufactured by complex and expensive technologies not suitable to address market and patient’s needs. T-CURX proprietary technologies (already validated in Phase I clinical trials) will overcome the current limitations to CAR-T cell therapies, lowering complexities and costs in manufacturing, thereby giving many more patients with both hematological malignancies and solid tumors access to these promising personalized medicines. Our scalable therapies enable more patients to have a chance to achieve complete and long-term remission. With our experienced team and innovative technologies, we aim at reducing high costs and complex manufacturing, expanding the limited spectrum of indications and focusing on additional target molecules and ultimately at establishing our technology as the gold-standard in CAR-T cell therapies.

“We believe the inspiring work atmosphere at IZB will accelerate our vision to revolutionize cancer therapy.”

Dr. Ulf Grawunder, CEO